January 31, 2020

Genovis AB (publ) to publish 2020 reports ahead of schedule

Regulatory
The Board of Directors of Genovis AB (publ) has decided to publish Q1- Q3 2020 reports ahead of schedule due to more efficient financial routines.

The new publication dates for the reports 2020 are:

Year-end Report             January 1 – December 31, 2019                  February 5

Interim Report                January 1 – March 31, 2020                        April 29

Half-Yearly Report          January 1 – June 30, 2020                          August 13

Interim report                 January 1 – September 30, 2020                 November 5

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233 fredrik.olsson@genovis.com

 

ABOUT GENOVIS

Genovis’ business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Stockholm and Erik Penser Bank is the Company’s Certified Adviser, certifiedadviser@penser.se, T: +46 (0)8-463 83 00.

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

 

Release
  • Svenska